Protocol for chemogenetic activation of basal ganglia D1-MSNs and behavioral assessments in a primate Parkinson’s disease model
Summary: A circuit-based gene therapy strategy for Parkinson’s disease (PD) has been shown to significantly reverse core symptoms in both murine and primate PD models. Here, we present a comprehensive workflow to specifically manipulate dopamine receptor D1-expressing medium spiny neurons by retrogr...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | STAR Protocols |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S266616672400635X |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846138437519802368 |
|---|---|
| author | Yefei Chen Zexuan Hong Ting Yan Yuyuan Zhu Jianbang Lin Taian Liu Ming Guo Mengqi Li Shijing Feng Ronghui Li Jianqing Zhang Siyang Chen Yi Yang Yuantao Li Zhonghua Lu |
| author_facet | Yefei Chen Zexuan Hong Ting Yan Yuyuan Zhu Jianbang Lin Taian Liu Ming Guo Mengqi Li Shijing Feng Ronghui Li Jianqing Zhang Siyang Chen Yi Yang Yuantao Li Zhonghua Lu |
| author_sort | Yefei Chen |
| collection | DOAJ |
| description | Summary: A circuit-based gene therapy strategy for Parkinson’s disease (PD) has been shown to significantly reverse core symptoms in both murine and primate PD models. Here, we present a comprehensive workflow to specifically manipulate dopamine receptor D1-expressing medium spiny neurons by retrograde adeno-associated virus (AAV) transduction and chemogenetic activation using a designer toolkit. We describe steps for AAV injections and PD primate model induction. We then detail behavioral measurements to assess the therapeutic efficacy of the therapy for motor symptoms. : Publisher’s note: Undertaking any experimental protocol requires adherence to local institutional guidelines for laboratory safety and ethics. |
| format | Article |
| id | doaj-art-1d22997db04f45b592380665f31feae6 |
| institution | Kabale University |
| issn | 2666-1667 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | STAR Protocols |
| spelling | doaj-art-1d22997db04f45b592380665f31feae62024-12-07T08:28:25ZengElsevierSTAR Protocols2666-16672024-12-0154103470Protocol for chemogenetic activation of basal ganglia D1-MSNs and behavioral assessments in a primate Parkinson’s disease modelYefei Chen0Zexuan Hong1Ting Yan2Yuyuan Zhu3Jianbang Lin4Taian Liu5Ming Guo6Mengqi Li7Shijing Feng8Ronghui Li9Jianqing Zhang10Siyang Chen11Yi Yang12Yuantao Li13Zhonghua Lu14Department of Anesthesiology, Affiliated Shenzhen Maternity & Child Healthcare Hospital, Southern Medical University, Shenzhen 518027, China; Shenzhen Key Laboratory for Molecular Biology of Neural Development, Shenzhen Technological Research Center for Primate Translational Medicine, Shenzhen-Hong Kong Institute of Brain Science, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, ChinaDepartment of Anesthesiology, Affiliated Shenzhen Maternity & Child Healthcare Hospital, Southern Medical University, Shenzhen 518027, China; Shenzhen Key Laboratory for Molecular Biology of Neural Development, Shenzhen Technological Research Center for Primate Translational Medicine, Shenzhen-Hong Kong Institute of Brain Science, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, ChinaShenzhen Key Laboratory for Molecular Biology of Neural Development, Shenzhen Technological Research Center for Primate Translational Medicine, Shenzhen-Hong Kong Institute of Brain Science, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China; Research Center for Primate Neuromodulation and Neuroimaging, Institute of Biomedical and Health Engineering, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, ChinaShenzhen Key Laboratory for Molecular Biology of Neural Development, Shenzhen Technological Research Center for Primate Translational Medicine, Shenzhen-Hong Kong Institute of Brain Science, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, ChinaShenzhen Key Laboratory for Molecular Biology of Neural Development, Shenzhen Technological Research Center for Primate Translational Medicine, Shenzhen-Hong Kong Institute of Brain Science, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China; Research Center for Primate Neuromodulation and Neuroimaging, Institute of Biomedical and Health Engineering, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China; University of Chinese Academy of Sciences, Beijing 100049, ChinaShenzhen Key Laboratory for Molecular Biology of Neural Development, Shenzhen Technological Research Center for Primate Translational Medicine, Shenzhen-Hong Kong Institute of Brain Science, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China; Research Center for Primate Neuromodulation and Neuroimaging, Institute of Biomedical and Health Engineering, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, ChinaShenzhen Key Laboratory for Molecular Biology of Neural Development, Shenzhen Technological Research Center for Primate Translational Medicine, Shenzhen-Hong Kong Institute of Brain Science, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China; Research Center for Primate Neuromodulation and Neuroimaging, Institute of Biomedical and Health Engineering, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, ChinaShenzhen Key Laboratory for Molecular Biology of Neural Development, Shenzhen Technological Research Center for Primate Translational Medicine, Shenzhen-Hong Kong Institute of Brain Science, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China; Research Center for Primate Neuromodulation and Neuroimaging, Institute of Biomedical and Health Engineering, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, ChinaShenzhen Key Laboratory for Molecular Biology of Neural Development, Shenzhen Technological Research Center for Primate Translational Medicine, Shenzhen-Hong Kong Institute of Brain Science, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, ChinaShenzhen Key Laboratory for Molecular Biology of Neural Development, Shenzhen Technological Research Center for Primate Translational Medicine, Shenzhen-Hong Kong Institute of Brain Science, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China; Research Center for Primate Neuromodulation and Neuroimaging, Institute of Biomedical and Health Engineering, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, ChinaShenzhen Key Laboratory for Molecular Biology of Neural Development, Shenzhen Technological Research Center for Primate Translational Medicine, Shenzhen-Hong Kong Institute of Brain Science, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China; Research Center for Primate Neuromodulation and Neuroimaging, Institute of Biomedical and Health Engineering, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, ChinaShenzhen Key Laboratory for Molecular Biology of Neural Development, Shenzhen Technological Research Center for Primate Translational Medicine, Shenzhen-Hong Kong Institute of Brain Science, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China; Research Center for Primate Neuromodulation and Neuroimaging, Institute of Biomedical and Health Engineering, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, ChinaShenzhen Key Laboratory for Molecular Biology of Neural Development, Shenzhen Technological Research Center for Primate Translational Medicine, Shenzhen-Hong Kong Institute of Brain Science, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China; Research Center for Primate Neuromodulation and Neuroimaging, Institute of Biomedical and Health Engineering, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China; University of Chinese Academy of Sciences, Beijing 100049, ChinaDepartment of Anesthesiology, Affiliated Shenzhen Maternity & Child Healthcare Hospital, Southern Medical University, Shenzhen 518027, China; Biomedical Research Institute, Hubei University of Medicine, Shiyan 442000, China; Corresponding authorShenzhen Key Laboratory for Molecular Biology of Neural Development, Shenzhen Technological Research Center for Primate Translational Medicine, Shenzhen-Hong Kong Institute of Brain Science, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China; Research Center for Primate Neuromodulation and Neuroimaging, Institute of Biomedical and Health Engineering, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China; University of Chinese Academy of Sciences, Beijing 100049, China; Biomedical Imaging Science and System Key Laboratory, Chinese Academy of Sciences, Shenzhen 518055, China; Corresponding authorSummary: A circuit-based gene therapy strategy for Parkinson’s disease (PD) has been shown to significantly reverse core symptoms in both murine and primate PD models. Here, we present a comprehensive workflow to specifically manipulate dopamine receptor D1-expressing medium spiny neurons by retrograde adeno-associated virus (AAV) transduction and chemogenetic activation using a designer toolkit. We describe steps for AAV injections and PD primate model induction. We then detail behavioral measurements to assess the therapeutic efficacy of the therapy for motor symptoms. : Publisher’s note: Undertaking any experimental protocol requires adherence to local institutional guidelines for laboratory safety and ethics.http://www.sciencedirect.com/science/article/pii/S266616672400635XHealth SciencesNeuroscienceBehavior |
| spellingShingle | Yefei Chen Zexuan Hong Ting Yan Yuyuan Zhu Jianbang Lin Taian Liu Ming Guo Mengqi Li Shijing Feng Ronghui Li Jianqing Zhang Siyang Chen Yi Yang Yuantao Li Zhonghua Lu Protocol for chemogenetic activation of basal ganglia D1-MSNs and behavioral assessments in a primate Parkinson’s disease model STAR Protocols Health Sciences Neuroscience Behavior |
| title | Protocol for chemogenetic activation of basal ganglia D1-MSNs and behavioral assessments in a primate Parkinson’s disease model |
| title_full | Protocol for chemogenetic activation of basal ganglia D1-MSNs and behavioral assessments in a primate Parkinson’s disease model |
| title_fullStr | Protocol for chemogenetic activation of basal ganglia D1-MSNs and behavioral assessments in a primate Parkinson’s disease model |
| title_full_unstemmed | Protocol for chemogenetic activation of basal ganglia D1-MSNs and behavioral assessments in a primate Parkinson’s disease model |
| title_short | Protocol for chemogenetic activation of basal ganglia D1-MSNs and behavioral assessments in a primate Parkinson’s disease model |
| title_sort | protocol for chemogenetic activation of basal ganglia d1 msns and behavioral assessments in a primate parkinson s disease model |
| topic | Health Sciences Neuroscience Behavior |
| url | http://www.sciencedirect.com/science/article/pii/S266616672400635X |
| work_keys_str_mv | AT yefeichen protocolforchemogeneticactivationofbasalgangliad1msnsandbehavioralassessmentsinaprimateparkinsonsdiseasemodel AT zexuanhong protocolforchemogeneticactivationofbasalgangliad1msnsandbehavioralassessmentsinaprimateparkinsonsdiseasemodel AT tingyan protocolforchemogeneticactivationofbasalgangliad1msnsandbehavioralassessmentsinaprimateparkinsonsdiseasemodel AT yuyuanzhu protocolforchemogeneticactivationofbasalgangliad1msnsandbehavioralassessmentsinaprimateparkinsonsdiseasemodel AT jianbanglin protocolforchemogeneticactivationofbasalgangliad1msnsandbehavioralassessmentsinaprimateparkinsonsdiseasemodel AT taianliu protocolforchemogeneticactivationofbasalgangliad1msnsandbehavioralassessmentsinaprimateparkinsonsdiseasemodel AT mingguo protocolforchemogeneticactivationofbasalgangliad1msnsandbehavioralassessmentsinaprimateparkinsonsdiseasemodel AT mengqili protocolforchemogeneticactivationofbasalgangliad1msnsandbehavioralassessmentsinaprimateparkinsonsdiseasemodel AT shijingfeng protocolforchemogeneticactivationofbasalgangliad1msnsandbehavioralassessmentsinaprimateparkinsonsdiseasemodel AT ronghuili protocolforchemogeneticactivationofbasalgangliad1msnsandbehavioralassessmentsinaprimateparkinsonsdiseasemodel AT jianqingzhang protocolforchemogeneticactivationofbasalgangliad1msnsandbehavioralassessmentsinaprimateparkinsonsdiseasemodel AT siyangchen protocolforchemogeneticactivationofbasalgangliad1msnsandbehavioralassessmentsinaprimateparkinsonsdiseasemodel AT yiyang protocolforchemogeneticactivationofbasalgangliad1msnsandbehavioralassessmentsinaprimateparkinsonsdiseasemodel AT yuantaoli protocolforchemogeneticactivationofbasalgangliad1msnsandbehavioralassessmentsinaprimateparkinsonsdiseasemodel AT zhonghualu protocolforchemogeneticactivationofbasalgangliad1msnsandbehavioralassessmentsinaprimateparkinsonsdiseasemodel |